Most pricing and treatment options are hidden until after checkout
Semaglutide, a long-acting GLP-1 agonist, exhibited a sustained weight decrease of approximately 15% of body weight in clinical studies, whereas tirzepatide, a combination GIP/GLP-1 agonist, attained a weight loss of up to 22.5% in the SURMOUNT trials [36,37]
This reaction destroys the targeted cells, making it an effective treatment for certain types of cancer and other medical conditions [251]
If the semaglutide-related fatigue lasts longer than expected, there are options to stay on the dose for longer or drop to a lower dose
Its important to note that these side effects may not appear immediately and can vary in intensity based on individual factors
doi:10.1007/s00234-007-0345-7